dr. lenz on breakthrough designation of encorafenib, binimetinib, and cetuximab in braf crc
Published 5 years ago • 379 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
8:16
encorafenib & binimetinib cetuximab for untreated braf v600e-mutant metastatic colorectal cancer
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
5:04
beacon: encorafenib plus cetuximab with or without binimetinib for braf v600e–mutant metastatic ...
-
2:13
dr. lenz on the benefit of regorafenib in crc
-
13:48
encorafenib, binimetinib, and cetuximab in braf v600e–mutated colorectal cancer
-
1:51
dr. eng discusses the beacon crc study in braf-mutated crc
-
9:28
new therapy options for braf-mutated mcrc
-
0:54
triplet therapy for certain patients with metastatic crc shows promise, but more research is needed
-
1:21
phase iii trial of denosumab for breast cancer risk reduction in brca1 carriers
-
1:18
safety lead-in data for beacon crc trial with triplet biologic regimen in mcrc
-
0:50
dr. bendell discusses two studies in braf-mutated crc
-
7:32
considerations when selecting an egfr inhibitor in metastatic colorectal cancer
-
9:27
fda approval in bladder cancer, breakthrough therapy designation in dlbcl, and more
-
3:14
encorafenib for braf-mutant colorectal cancer
-
2:26
dr. flaherty on the columbus trial updates in melanoma
-
2:45
ulixertinib in tumors with braf fusions, non-v600e or non-v600k braf mutations
-
11:05
keynote-042: should pembrolizumab replace chemo for broader population with adv. nsclc? (bmic-038)
-
1:15
netrf session 5 epigenietic regulators of intestinal endocrine cells and carcinoid tumors
-
6:53
sequencing in dtc: lenvatinib and sorafenib